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Medicare Coverage of Aducanumab — Implications for State
Budgets
Rachel E. Sachs, J.D., M.P.H., and Nicholas Bagley, J.D.

A

ducanumab (Aduhelm), the
controversial $56,000-per-year
Alzheimer’s disease drug approved
by the Food and Drug Administration (FDA) in June 2021, has
the potential to cost the federal
government many billions of dollars — more, by one estimate,
than it spends on agencies such
as the Environmental Protection
Agency or the National Aeronautics and Space Administration.
The drug’s extraordinary price tag
helps explain why, soon after its
approval, the Centers for Medicare and Medicaid Services (CMS)
opened a national coverage determination to decide whether

and under what circumstances
Medicare would pay for it.1
A restrictive coverage determination could save the federal government a lot of money — but,
as a recent letter from the National Association of Medicaid
Directors (NAMD) noted, it would
also shift substantial costs to the
states.2 The emerging debate over
who will pay for aducanumab has
important implications for Medicare spending, state fiscal health,
and existing laws requiring Medicare and Medicaid to cover nearly
all approved drugs, no matter
their prices and no matter how
poorly they work.

n engl j med 385;22
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Usually, Medicare coverage of
FDA-approved drugs is a foregone
conclusion: the clinical evidence to
support FDA approval is deemed
sufficient to show that a product
is “reasonable and necessary” for
the treatment of an illness or injury, as the Medicare statute requires. But aducanumab is a special case. In granting accelerated
approval to aducanumab, the FDA
concluded that the drug’s ability
to reduce amyloid plaques was
reasonably likely to translate into
clinical benefits. But this claim
is hotly contested and was not
presented to the FDA’s advisory
committee, which voted against
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recommending approval of the
drug because of the lack of a
demonstrated clinical benefit.
Although the FDA instructed the
drug’s manufacturer, Biogen, to
conduct additional trials over the
next 9 years, and although the
FDA may withdraw approval if
the confirmatory trials fail to
demonstrate a clinical benefit, the
withdrawal process is typically
long and highly contentious.
In making its coverage determination, CMS could point to
the thin evidence base supporting the drug as a reason to limit
Medicare coverage. Some other
payers have restricted coverage
of aducanumab, as have several
influential health systems. A restrictive coverage determination,
however, would in many cases
make the states responsible for
paying for aducanumab. More
than 12 million people (mostly
low-income older or disabled
Americans) are dually eligible for
Medicare and Medicaid. The federally run Medicare program
covers most medical expenses for
these beneficiaries, and Medicaid,
the joint state–federal program,
picks up the remaining costs. As
a result, Medicaid is usually responsible only for taking care of
Medicare’s 20% cost-sharing requirement, at the most.
As a legal matter, however,
state Medicaid programs are required to cover nearly all FDAapproved drugs — even drugs
that Medicare chooses not to
cover. Medicare’s refusal to cover
aducanumab would therefore leave
states fully responsible for the
drug’s costs and associated expenses for dual-eligible beneficiaries. As the NAMD noted in
its comments on the national
coverage determination, the budgetary effects of CMS’s decision

2020

could be immense.2 The Medicaid directors encouraged CMS to
cover aducanumab, not because
of its clinical value for patients,
but because they are concerned
about “shifting costs for such
therapies to state Medicaid programs.”
The fiscal implications for
states are serious. Unlike the federal government, states can’t run
budget deficits, which means
they would have to raise taxes or
reduce spending in other areas
to pay for aducanumab. Similar
budgetary pressures led states to
restrict the availability of sofosbuvir (Sovaldi) for the treatment of
hepatitis C in the years after its
release, even though the drug was
curative. These restrictive policies
were successfully challenged in
court as unlawful, but a delay
in full coverage allowed states to
spread the costs of sofosbuvir —
a treatment that requires a single
course, rather than long-term use
— over several years. Aducanu
mab may put states in a similarly
difficult fiscal position, notwithstanding the thin evidence that
it will help patients with Alzhei
mer’s disease.
State Medicaid programs have
previously expressed concern regarding the budgetary effects of
coverage requirements for prescription drugs — especially
those that, like aducanumab, have
been granted accelerated approval.
Under this expedited-approval
pathway, the FDA can approve
drugs on the basis of a surrogate
end point (such as a reduction in
amyloid plaques, in the case of
aducanumab), rather than a true
clinical end point. In 2017, Massachusetts requested a waiver from
CMS that would have allowed its
Medicaid program not to cover
prescription drugs for which there

is limited evidence of clinical efficacy.
Although CMS denied Massachusetts’ request, it later permitted Tennessee’s Medicaid program
to restrict access to some drugs
under certain conditions. More
recently, the Medicaid and CHIP
Payment and Access Commission
(MACPAC) recommended changing the ways in which state Medicaid programs pay for drugs
that are granted accelerated approval.3 For now, however, states
remain responsible for covering
all FDA-approved drugs, including those that have no demonstrated clinical benefits.
A proposed reimbursement decision is expected in January 2022,
with the agency’s final decision
expected in April. At the same
time, CMS’s coverage-determination process is structured to consider only whether aducanumab
is “reasonable and necessary”
for treating Alzheimer’s disease.
CMS will assess the clinical evidence supporting the drug’s use,
but it probably cannot consider
the implications of any potential
ruling for state budgets.
The state Medicaid directors
did present an alternative for CMS
to consider. States are currently
permitted to exclude from coverage only narrow classes of FDAapproved drugs, such as cosmetic
products and fertility drugs. But
CMS is empowered to “update
the list of drugs or classes of
drugs . . . or their medical uses”
when it determines that drugs
are subject to “inappropriate use.”4
The directors suggested that the
agency could make such a determination and allow state Medicaid programs to exclude aducanu
mab from coverage.2 But CMS
has previously suggested that using a drug for its medically ac-
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cepted indication does not constitute inappropriate use. (This
issue arose in the context of a
1998 memo explaining why Medicaid programs must pay for
erectile-dysfunction medication.5)
If the agency adheres to this position, CMS would not be able to
use this legal pathway to relieve
states of their responsibility to
cover aducanumab for the treatment of Alzheimer’s disease.
The federal government could
explore other options. CMS might,
for example, revisit its decision to
reject Medicaid waivers similar to
the one sought by Massachusetts
in 2017. Such waivers could lift
the prevailing rules governing
drug coverage and allow states to
exclude products, like aducanu
mab, for which clinical evidence
to support approval is lacking. If
the traditional waiver process is
too slow or cumbersome, CMS
could explore similar waiver-based
solutions through the CMS Innovation Center.
The cleanest solutions are likely to come from Congress, though
the politics surrounding the first
drug approved for treating Alz
heimer’s disease in decades will

be tricky to navigate. The legislature, for example, could pass a
law automatically extending any
Medicare national coverage determination to Medicaid or allowing states to make their own coverage determinations in cases in
which CMS has made a national
coverage determination. Alternatively, Congress could adopt new
legislation specifying that state
Medicaid programs need not cover aducanumab, much as it did in
2005 when it allowed Medicaid
programs to exclude erectile-dysfunction drugs. More broadly,
Congress could grant states coverage flexibility when it comes to
the entire set of drugs that have
been granted accelerated approval.
We believe that both the federal government and the states
deserve better policy options in
the face of a historic drug approval. Protecting state budgets
shouldn’t require Medicare to
cover an expensive drug with unproven clinical benefits, and Congress should take steps to fix
this problem. Perhaps aducanu
mab’s high price will finally provide the impetus for revisiting
Medicare’s and Medicaid’s exist-

ing commitments to covering all
FDA-approved drugs.
Disclosure forms provided by the authors
are available at NEJM.org.
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